^
    1m
    Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases. (PubMed, J Hematop)
    MEF2B immunohistochemistry can aid in distinguishing FL from MZL in diagnostically challenging cases.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    1m
    RG1716009: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028
    Trial completion date
    |
    Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
    1m
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    1m
    CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma. (PubMed, Am J Clin Pathol)
    CEACAM1 is frequently expressed in MCL and in subsets of other mature B-cell neoplasms and MM. These findings support further investigation of CEACAM1 as a biologically relevant marker and potential therapeutic target in selected lymphoid malignancies.
    Retrospective data • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CEACAM5 (CEA Cell Adhesion Molecule 5) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    Chr t(11;14)
    1m
    Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> May 2027
    Trial completion date
    |
    CD34 (CD34 molecule)
    1m
    MT2015-29: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (clinicaltrials.gov)
    P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    2ms
    Molecular and Cellular Characterization of MALT Lymphoma (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, International Extranodal Lymphoma Study Group (IELSG) | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    2ms
    Coexistence of Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Transthyretin Amyloidosis in an Elderly Japanese Patient With Splenic Marginal Zone Lymphoma: An Autopsy Case Report. (PubMed, Cureus)
    Aspiration pneumonia temporarily improved with ceftriaxone sodium hydrate; however, the patient died of sudden deterioration of oxygenation on the 49th hospital day...This case highlights the potential pathophysiological interplay of multiple immune-mediated and neoplastic conditions in elderly patients, underscoring the importance for clinicians to recognize that patients with SMZL may have coexisting autoimmune diseases such as MPA and SLE. In particular, in elderly patients, the possibility of occult ATTR should also be considered.
    Journal
    |
    CRP (C-reactive protein) • MPO (Myeloperoxidase)
    2ms
    Gastrointestinal-Predominant ALK-Negative Systemic Anaplastic Large Cell Lymphoma Presenting as Fever of Unknown Origin: Case Report. (PubMed, Korean J Helicobacter Up Gastrointest Res)
    The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • TNFRSF8 expression • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone
    2ms
    ROMA: Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=144, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide
    2ms
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2ms
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)